Business Segments · Impairment Charges
Biotechnology — Impairment Charges
This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
StatementSegment
CategoryRisk
SignalLower is better
VolatilityVolatile
First reportedQ1 2023
Last reportedQ3 2025
How to read this metric
An increase signals potential overvaluation of past acquisitions or deteriorating business prospects.
Detailed definition
Non-cash charges recognized when the carrying value of an asset or goodwill within the biotechnology segment exceeds its...
Peer comparison
Reported periodically by all public companies under GAAP/IFRS when asset values are tested.
Metric ID:
dhr_segment_biotechnology_impairment_chargesHistorical Data
7 periods
| Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q3 '24 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|
| Value | $13.50M | $13.50M | $13.50M | $13.50M | $0.00 | $0.00 | $86.00M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | -100.0% | — | — |
| YoY Change | — | — | — | — | -100.0% | — | — |
Range$0.00 – $86.00M
CAGR+243.6%
Avg YoY Growth-100.0%
Median YoY Growth-100.0%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Danaher's biotechnology — impairment charges?
- Danaher (DHR) reported biotechnology — impairment charges of $86.00M in Q3 2025.
- What does biotechnology — impairment charges mean?
- A write-down of asset values due to a decline in their expected future worth.